Biosyent Inc. - Asset Resilience Ratio
Biosyent Inc. (RX) has an Asset Resilience Ratio of 14.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore RX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Biosyent Inc.'s Asset Resilience Ratio has changed over time. See Biosyent Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets Composition Over Time
This chart breaks down Biosyent Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Biosyent Inc. balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$6.83 Million | 14.29% |
| Total Liquid Assets | CA$6.83 Million | 14.29% |
Asset Resilience Insights
- Moderate Liquidity: Biosyent Inc. has 14.29% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Biosyent Inc. Industry Peers by Asset Resilience Ratio
Compare Biosyent Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Krka d. d
WAR:KRK |
Drug Manufacturers - Specialty & Generic | 11.18% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263 |
Drug Manufacturers - Specialty & Generic | 6.08% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Biosyent Inc. (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Biosyent Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.25% | CA$3.83 Million ≈ $2.77 Million |
CA$41.36 Million ≈ $29.92 Million |
-41.99pp |
| 2023-12-31 | 51.24% | CA$21.28 Million ≈ $15.39 Million |
CA$41.53 Million ≈ $30.04 Million |
-0.21pp |
| 2022-12-31 | 51.45% | CA$20.83 Million ≈ $15.07 Million |
CA$40.49 Million ≈ $29.29 Million |
+24.07pp |
| 2021-12-31 | 27.38% | CA$10.18 Million ≈ $7.36 Million |
CA$37.17 Million ≈ $26.89 Million |
+11.63pp |
| 2020-12-31 | 15.75% | CA$5.29 Million ≈ $3.82 Million |
CA$33.57 Million ≈ $24.28 Million |
-11.81pp |
| 2019-12-31 | 27.55% | CA$8.53 Million ≈ $6.17 Million |
CA$30.97 Million ≈ $22.40 Million |
+3.21pp |
| 2018-12-31 | 24.34% | CA$7.59 Million ≈ $5.49 Million |
CA$31.19 Million ≈ $22.56 Million |
-2.29pp |
| 2017-12-31 | 26.63% | CA$6.69 Million ≈ $4.84 Million |
CA$25.10 Million ≈ $18.16 Million |
+23.08pp |
| 2016-12-31 | 3.55% | CA$683.20K ≈ $494.22K |
CA$19.25 Million ≈ $13.92 Million |
-32.89pp |
| 2015-12-31 | 36.44% | CA$5.32 Million ≈ $3.85 Million |
CA$14.61 Million ≈ $10.57 Million |
+27.04pp |
| 2014-12-31 | 9.39% | CA$999.97K ≈ $723.36K |
CA$10.64 Million ≈ $7.70 Million |
-49.16pp |
| 2005-12-31 | 58.55% | CA$600.00K ≈ $434.03K |
CA$1.02 Million ≈ $741.28K |
-- |
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form produc… Read more